BLACK DIAMOND THERAPEUTICS, INC.

Analyst Reco. Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
4.74 ^USD	-5.95%		-9.54%	+68.68%

May. 16	HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating	MT
May. 09	Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating	May. 16	MT
Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating	Apr. 08	MT
Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target	23-07-14	MT
Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2	23-06-30	MT
HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11	23-06-28	MT
Wedbush Upgrades Black Diamond Therapeutics to Outperform From Neutral, Adjusts Price Target to $10 From $3	23-06-27	MT
Wedbush Lowers Price Target for Black Diamond Therapeutics to $3 From $4, Maintains Neutral Rating	22-05-12	MT
Berenberg Bank Adjusts Black Diamond Therapeutics Price Target to $16 From $34, Maintains Buy Rating	22-04-01	MT
Wedbush Downgrades Black Diamond Therapeutics to Neutral From Outperform, Citing BDTX-1535 Timeline, Likely BDTX-189 Discontinuation, 'Tough' Financing Environment; PT to $4 From $22	22-03-29	MT
HC Wainwright Downgrades Black Diamond Therapeutics to Neutral From Buy	22-03-22	MT
Stifel Adjusts Price Target on Black Diamond Therapeutics to $4 From $10, Reiterates Hold Rating	22-03-18	MT
BLACK DIAMOND THERAPEUTICS : Stifel Starts Black Diamond Therapeutics at Hold With $10 Price Target	21-09-30	MT
BLACK DIAMOND THERAPEUTICS : Wedbush Lowers PT for Black Diamond Therapeutics to $22 From $48 Following BDTX-189 Data, Reiterates Outperform Rating	21-08-17	MT
BLACK DIAMOND THERAPEUTICS : Berenberg Bank Adjusts Black Diamond Therapeutics PT to $34 From $58, Maintains Buy Rating	21-08-17	MT
BLACK DIAMOND THERAPEUTICS : Wedbush Removes Outperform-Rated Black Diamond Therapeutics From Best Ideas List; Price Target is $48	21-05-21	MT
BLACK DIAMOND THERAPEUTICS : Wedbush Adds Outperform-Rated Black Diamond Therapeutics to Best Ideas List; Price Target is $48	21-03-29	MT
BLACK DIAMOND THERAPEUTICS : Wedbush Adjusts Price Target on Black Diamond Therapeutics to $48 From $45, Keeps Outperform Rating	21-03-26	MT
BLACK DIAMOND THERAPEUTICS : Wedbush Starts Black Diamond Therapeutics at Outperform With $45 Price Target	21-01-07	MT
BLACK DIAMOND THERAPEUTICS : Berenberg Starts Black Diamond Therapeutics at Buy With $58 Price Target	20-11-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer